MGC Diagnostics Corporation to Report First Quarter Fiscal 2013 Financial Results on Tuesday, March 5, 2013

  MGC Diagnostics Corporation to Report First Quarter Fiscal 2013 Financial
                      Results on Tuesday, March 5, 2013

PR Newswire

ST. PAUL, Minn., Feb. 25, 2013

ST. PAUL, Minn., Feb. 25, 2013 /PRNewswire/ -- MGC Diagnostics Corporation
(NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology
company, today scheduled a conference call to discuss its financial results
for the first quarter of fiscal year 2013, ended January 31, 2013. The call
will be at 4:30 p.m. ET on Tuesday, March 5, 2013. The Company will report
financial results for the first quarter of fiscal year 2013 after the markets
close on Tuesday, March 5, 2013.

(Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

Participants can dial (877) 317-6789 or (412) 317-6789 to access the
conference call, or listen via a live Internet webcast on the Company's
website at www.mgcdiagnostics.com. A replay of the conference call will be
available by dialing (877) 344-7529 or (412) 317-0088, confirmation code
10025649, through March 12, 2013. A webcast replay of the conference call will
be accessible on the Company's website at www.mgcdiagnostics.com for 90 days.

About MGC Diagnostics

MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation), is
a global medical technology company dedicated to cardiorespiratory health
solutions. MGC Diagnostics develops, manufactures and markets non-invasive
diagnostic systems. This portfolio of products provide solutions for disease
detection, integrated care, and wellness across the spectrum of
cardiorespiratory healthcare. The Company's products are sold internationally
through distributors and in the United States through a direct sales force
targeting heart and lung specialists located in hospitals, university-based
medical centers, medical clinics, physicians' offices, pharmaceutical
companies, medical device manufacturers, and clinical research organizations
(CROs). For more information about MGC Diagnostics, visit
www.mgcdiagnostics.com.

Contact: Wesley W. Winnekins        Joe Dorame, Robert Blum, Joe
                                               Diaz
         MGC Diagnostics                       Lytham Partners, LLC
         Corporation
         Chief Financial Officer     (602) 889-9700
         (651) 484-4874      mgcd@lythampartners.com

SOURCE MGC Diagnostics Corporation

Website: http://www.mgcdiagnostics.com
 
Press spacebar to pause and continue. Press esc to stop.